On July 29, 2026, Johnson & Johnson announced the completion of its acquisition of Firefly Bio, a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances the company’s ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers. Wilson Sonsini Goodrich & Rosati advised Firefly Bio on the transaction.

The Wilson Sonsini team that advised Firefly Bio on the transaction was led by Jason Breen, Ross Tanaka, Karen Deschaine, and Phillip McGill. The team also included:

Mergers & Acquisitions
Kaleigh Hawkins-Schulz

Corporate
Kyrsten Lundh
Alison Sechrest
Sean Donohue
Erin Wolter

Technology Transactions
Miranda Biven
Nellie Brutocao

Employee Benefits and Compensation
Brandon Gantus
Jason Chan

Employment Law
Matt Gorman

Tax
Myra Sutanto Shen
Rob Sherrill

Antitrust and Competition
Michelle Yost Hale
Kimberley Biagioli

Patents and Innovations
Julia Minitti
Grant Margulieux

Data, Privacy, and Cybersecurity
Matthew Staples
Michael O’Brien

For more information, please see Johnson & Johnson’s news release. Additional coverage can be found on The Wall Street Journal, Reuters, and Fierce Pharma.